Company news

NovoCure Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance

October 29, 2026

Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement

October 28, 2026

Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

October 1, 2026

Novocure to Report Third Quarter 2026 Financial Results

October 1, 2026

Novocure Reports Second Quarter 2026 Financial Results

July 23, 2026

Novocure to Report Second Quarter 2026 Financial Results

July 1, 2026

Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer

June 30, 2026

Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma

June 18, 2026

Novocure Reports First Quarter 2026 Financial Results

April 30, 2026

Novocure to Report First Quarter 2026 Financial Results

March 31, 2026

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

March 25, 2026

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

March 1, 2026

Novocure to Participate in 2026 Leerink Global Healthcare Conference

February 27, 2026

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

February 25, 2026

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

February 23, 2026

U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

February 11, 2026

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

January 11, 2026

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

December 21, 2025

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

November 30, 2025

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

November 25, 2025

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

November 11, 2025

Novocure Reports Third Quarter 2025 Financial Results

October 29, 2025

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

October 14, 2025

Novocure to Report Third Quarter 2025 Financial Results

September 30, 2025

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

September 28, 2025

Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

September 14, 2025

Novocure Announces Upcoming Investor Events

August 27, 2025

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

August 24, 2025

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

August 19, 2025

Novocure Reports Second Quarter 2025 Financial Results

July 23, 2025

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

June 30, 2025

Novocure to Report Second Quarter 2025 Financial Results

June 29, 2025

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 30, 2025

Novocure Reports First Quarter 2025 Financial Results

April 23, 2025

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

April 22, 2025

Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

April 21, 2025

Novocure to Report First Quarter 2025 Financial Results

March 31, 2025

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

March 3, 2025

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

February 26, 2025

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

January 21, 2025

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

January 12, 2025

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

January 2, 2025

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

December 1, 2024

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

December 1, 2024

Novocure to Participate in Upcoming Investor Conferences

November 26, 2024

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

November 20, 2024

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

November 20, 2024

Novocure Reports Third Quarter 2024 Financial Results

October 29, 2024

Novocure Appoints Christoph Brackmann as Chief Financial Officer

October 29, 2024

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

October 14, 2024

Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.